{"id":"W4385782360","doi":"10.1016/j.jtho.2023.08.010","title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Ceritinib; Internal medicine; Hazard ratio; Clinical endpoint; ALK inhibitor; Confidence interval; Adverse effect; Oncology; Gastroenterology; Randomized controlled trial; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003007873,0.001020928,0.001601454,0.0002151623,0.0003107962,0.001101959,0.000640285,0.0008118184,0.003537333],"category_scores_gemma":[0.002556171,0.0002260804,0.002305919,0.0002977736,0.0004685152,0.0005524315,0.0002311108,0.002271564,0.0006272864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000978798,"about_ca_system_score_gemma":0.001339322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007750405,"about_ca_topic_score_gemma":0.002874225,"domain_scores_codex":[0.9991928,0.0005265611,0.00005212689,0.00008399614,0.00006590813,0.0000785795],"domain_scores_gemma":[0.9986966,0.000416953,0.0003941251,0.0001087365,0.00008982042,0.0002939237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.93428,0.004938406,0.00278138,0.0008604015,0.002272464,0.0001311486,0.0001267536,0.000839136,0.006924361,0.0001214018,0.001896654,0.04482777],"study_design_scores_gemma":[0.8383476,0.1377004,0.01478761,0.0001670574,0.002359565,0.0002940078,0.00005892961,0.001075469,0.002177132,0.0004081964,0.00258742,0.0000366459],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835149,0.01012738,0.0004743001,0.0008198974,0.0002057404,0.001168639,0.001053977,0.00009059102,0.002544554],"genre_scores_gemma":[0.9921788,0.002787567,0.0006349319,0.0006356917,0.0002086809,0.000781926,0.001552352,0.00002084409,0.001199211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003537333,"threshold_uncertainty_score":0.01590735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04549059461048759,"score_gpt":0.5245308825252416,"score_spread":0.479040287914754,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}